Genmab A/S
General ticker "GNMSF" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $14.4B (TTM average)
Genmab A/S follows the US Stock Market performance with the rate: 43.6%.
Estimated limits based on current volatility of 1.4%: low 314.21$, high 322.52$
Factors to consider:
- Total employees count: 548 as of 2019
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [246.01$, 376.55$]
- 2024-12-30 to 2025-12-30 estimated range: [238.52$, 367.19$]
Financial Metrics affecting the GNMSF estimates:
- Negative: with PPE of 26.5 at the end of fiscal year the price was very high
- Positive: Operating profit margin, % of 32.30 > 18.64
- Positive: Return on assets ratio (scaled to [-100,100]) of 13.77 > 6.04
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 89.57 > 63.39
- Negative: Industry earnings per price (median), % of -22.08 <= 0
- Positive: Inventory ratio change, % of 0.37 <= 0.84
- Positive: 0.33 < Operating cash flow per share per price, % of 5.34
Short-term GNMSF quotes
Long-term GNMSF plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | DKK8,482.00MM | DKK14,595.00MM | DKK16,474.00MM |
| Operating Expenses | DKK5,529.00MM | DKK8,328.00MM | DKK11,153.00MM |
| Operating Income | DKK2,953.00MM | DKK6,267.00MM | DKK5,321.00MM |
| Non-Operating Income | DKK1,030.00MM | DKK678.00MM | DKK316.00MM |
| Interest Expense | DKK13.00MM | DKK21.00MM | DKK27.00MM |
| R&D Expense | DKK4,181.00MM | DKK5,562.00MM | DKK7,630.00MM |
| Income(Loss) | DKK3,983.00MM | DKK6,945.00MM | DKK5,637.00MM |
| Taxes | DKK975.00MM | DKK1,493.00MM | DKK0.00MM |
| Profit(Loss)* | DKK3,008.00MM | DKK3,869.00MM | DKK4,352.00MM |
| Stockholders Equity | DKK22,196.00MM | DKK27,282.00MM | DKK31,610.00MM |
| Inventory | DKK0.00MM | DKK0.00MM | DKK57.00MM |
| Assets | DKK24,627.00MM | DKK30,119.00MM | DKK35,289.00MM |
| Operating Cash Flow | DKK2,228.00MM | DKK3,912.00MM | DKK7,380.00MM |
| Capital expenditure | DKK252.00MM | DKK317.00MM | DKK376.00MM |
| Investing Cash Flow | DKK-961.00MM | DKK-2,761.00MM | DKK-1,282.00MM |
| Financing Cash Flow | DKK-420.00MM | DKK-789.00MM | DKK-606.00MM |
| Earnings Per Share** | DKK46.00 | DKK59.17 | DKK66.64 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.